COLORADO SPRINGS, Colo.,
Nov. 5, 2014 /PRNewswire/
-- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, is closely monitoring the CNN reporting of the
outcome of the State by State voting to legalize medical cannabis.
Target States in this voting session are Washington DC, Florida, Oregon, and Alaska.
Please visit:
http://www.cnn.com/2014/11/04/politics/marijuana-2014
The Company believes the Washington
DC, approval is the most significant. Being the center of
our federal political influential movements, it plays a key role
influencing medical cannabis state-by-state initiatives as well as
Federal laws governing the medical research on this plant.
Please visit:
http://money.cnn.com/2014/10/29/news/economy/legal-pot-vote
Currently, 23 states and the District
of Columbia have passed laws allowing some degree of medical
use of cannabis. With this as the backdrop, the Company believes
this could lead to further acceptance and improvement of regulatory
environment around medical cannabis in the United States and around the World,
continuing with the domino effect that will benefit patients who
have to rely on medical marihuana and deserve to receive quality
assured medication in the context of the general healthcare.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently,
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and
neurological conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.